Biosimilars – Current Treatment – Biosimilars | Current Treatment | Landscape | US/EU
In the last decade, the biosimilar therapy market has been growing, led mainly by two therapeutic areas: immunology and oncology. It now continues to expand into new fields. To enhance this growth, it is especially relevant to understand physicians’ perceptions of currently available biosimilars, elucidate their decision-making process, and determine the most relevant attributes a biosimilar should have. Based on Clarivate’s primary market research in the United States, France, and Germany with physicians from six specialties (gastroenterologists, endocrinologists, nephrologists, rheumatologists, medical oncologists, and hematologist-oncologists), our clients will better understand physicians’ experience with and attitude toward biosimilars and understand the evolution of biosimilars over the last three years (2020, 2021, and 2022).
Questions answered in this report:
- Understand current biosimilar use. What are the current levels of prescribing biosimilars among physicians from different specialties? How do physicians perceive current biosimilars?
- Understand the drivers, barriers, and physician attitudes regarding biosimilar uptake. What are the greatest drivers of/barriers to biosimilar use? How familiar with biosimilars are physicians from different specialties? How similar do physicians perceive biosimilars and reference brands to be? Are physicians aware of the pharmacy-level substitution rules in their own country, and would they expect to prevent this substitution? What are physicians’ opinions of indication extrapolation?
- Future use. Which types of biosimilar manufacturers do physicians trust most? How will physicians adopt biosimilars initially, and will adoption vary by specialty? Will physician uptake be affected by biosimilar price/reimbursement policies? Will physicians use new biologics, depending on their profile, once biosimilars are available? How will physicians choose between multiple biosimilars of the same reference product?
Scope
Markets covered: United States, France, and Germany.
Primary research: Online quantitative survey of 550 physicians from six specialties—endocrinologists (90), gastroenterologists (92), nephrologists (91), rheumatologists (90), hematologist-oncologists (98), and medical oncologists (89).
Table of contents
- Biosimilars - Current Treatment - Biosimilars | Current Treatment | Landscape | US/EU
- Current Treatment Physician Insights Landscape US/EU November 2022
Nuria Carmona, Ph.D., is an analyst on the Biosimilars team at Clarivate. Previously, she developed her scientific career in the field of cancer immunotherapy, nanotechnology, and molecular oncology. Dr. Carmona also worked as a pharmaceutical consultant at Anima Strategic Consulting. She received her doctorate from the University of Santiago de Compostela in Spain. She also holds an M.Sc. in drug research, development, and control from the University of Barcelona and a B.Sc. in biotechnology from the Autonomous University of Barcelona.
Hamzah Aideed, M.Sc., is a manager on the Biosimilars team at Clarivate. His team conducts both primary and secondary market research to provide in-depth analysis and key insights into biosimilars and the biopharmaceutical industry. Previously, Mr. Aideed was a senior research executive in consulting at McCann Health, specializing in the design and execution of advanced qualitative and quantitative research methodologies for bespoke ad-hoc consulting projects. He holds an M.Sc. in biotechnology, bioprocessing, and business management from the University of Warwick and a B.Sc. in biological chemistry from Aston University in Birmingham.